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Abstract 
Objective: Survival benefit with adjuvant therapy was shown in patients with Stage III colo-
rectal cancer (CRC). This study evaluates long-term (10-year) outcome in patients with CRC 
randomly  assigned  to  adjuvant  5-Fluorouracil/Leucovorin  (5FU+LV)  or  5-FU/Levamisole 
(5FU+LEV). 
Methods: Between 1990 and 1995, 398 patients with curatively resected Stage II-III CRC were 
randomly assigned to adjuvant 5FU+LV or 5FU+LEV for 12 months.  
Results: No difference was evident in 10-year relapse-free or overall survival between study 
groups. Grade III toxicity was similar between groups; however, neurotoxicity was signifi-
cantly greater with 5FU+LEV (p=0.02) and gastrointestinal toxicity with 5FU+LV (p=0.03). 
Female patients treated with 5FU+LEV had improved overall survival. 
Conclusions: Adjuvant treatment of CRC is still based on leucovorin modulated fluorouracil. 
The long-term follow-up results of this trial indicate that the adjuvant treatment of Stage II-III 
CRC with 5FU+LV or 5FU+LEV is equally effective. The finding of improved survival in female 
subjects treated with 5FU+LEV warrants further study to determine if Levamisole is a better 
modulator of 5-FU than Leucovorin in this patient subset. 
Key words: colorectal cancer, adjuvant chemotherapy, 5-fluorouracil, leucovorin, levamisole, sur-
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Introduction 
Colorectal  cancer  is  a  major  cause  of  death 
worldwide1.  As  the  risk  of  disease-recurrence  and 
cancer-specific mortality in patients with tumors in-
vading the bowel wall or regional lymphatics is high, 
adjuvant therapies have been pursued as a means to 
improve  survival2.  The  first  evidence  of  a  survival 
benefit  for  adjuvant  chemotherapy  was  reported  in 
the NSABP-C-01 study, the combination of semustine, 
vincristine  and  5-fluorouracil  (MOF)  was  shown  to 
improve  5-year  disease-free  (DFS)  and  overall  sur-
vival (OS) as compared to adjuvant immunotherapy 
with BCG or no further treatment3. However, the DFS 
and OS benefit associated with adjuvant MOF chem-
otherapy  disappeared  after  10  years4. An  early  me-
ta-analysis indicated a small OS benefit with adjuvant 
non-modulated  5FU  indicating  the  need  for  further 
adjuvant therapy trials in AJCC Stage III CRC5. The 
addition  of  the  antihelminthic  agent,  Levamisole 
(LEV), to 5FU was first evaluated in the context of a 
randomized  clinical  trial  by  the  NCCTG6.  In  a 
three-arm clinical trial, the combination of 5FU+LEV 
administrated for 12 months was found to be superior 
to either surgery alone or surgery followed by LEV 
alone. 5-FU+LEV reduced the recurrence rate by 40% 
and the death rate by 33% in Dukes’ C colon cancer. A 
subsequent trial (INT-0035) that randomized patients 
with Dukes’B2 and C colon cancer to surgery alone, or 
one year of adjuvant LEV or 5FU+LEV confirmed the 
efficacy of the 5FU and LEV combination in terms of 
improved DFS and OS. The results of this trial7-9, es-
tablished adjuvant therapy for Stage III colon cancer 
as a standard of care by the National Cancer Institute 
consensus development panel10. The activity of leu-
covorin  (LV)-modulated  5-FU  in  metastatic  colon 
cancer  led  to  the  evaluation  of  this  regimen  in  the 
adjuvant setting. The NSABP C-03 trial randomized 
patients  with  Dukes’  B  and  C  to  adjuvant  bolus 
5FU-LV and the MOF combination11.  
Treatment with LV-modulated 5FU resulted in a 
significant improvement in outcome over MOF. The 
International  Multicentre  Pooled  Analysis  of  Colon 
Cancer Trials (IMPACT) assessed over 1,400 patients 
with Stage II/III colon cancer randomized to 6 months 
of  5FU+LV  or  post-operative  observation  (IMPACT, 
1995). Adjuvant 5FU+LV significantly improved DFS 
by 35% and reduced mortality by 22%. A later pooled 
analysis demonstrated a significant DFS and OS ben-
efit  of  both  LV  and  LEV-modulated  5FU  adjuvant 
therapy  in  Stage  II/III  when  compared  to  surgery 
alone across all patient subsets12. Several groups em-
barked on clinical trials comparing the two forms of 
5FU-  based  adjuvant  therapy
12-22.  A  three-arm  trial 
demonstrated  that  a  short  6-month  course,  dose 
dense, three-drug regimen of 5FU+LV+LEV was su-
perior to 5FU+LEV given for either 6 or 12 months17. 
NSABP  C-04  compared  three  adjuvant  treatment 
regimens, 5FU+LV and 5FU+LEV and 5FU+LV+LEV, 
finding  similar  efficacy  with  the  two  drug  therapy 
and no incremental benefit to the three drug combi-
nation18. The INT 008921 and the adjCCA-0119,22 trials 
compared  various  dose  intensities  and  durations  of 
5FU+LV  to  5FU+LEV  and  suggested  superiority  of 
modulation with Leucovorin over Levamisole, at least 
for treatment lasting 6 months only. In the majority of 
these trials the reported follow-up is 5 years. Very few 
studies report a longer follow up of up to 10 years19. 
We report a long-term follow-up of a study compar-
ing adjuvant 5FU+Levamisole to 5FU+Leucovorin for 
12 months in Stage II and III CRC. The present clinical 
trial was designed in 1990 when the initial results of 
adjuvant  clinical  trials  showing  the  benefit  of 
5FU+LEV  were  reported.  The  original  aim  of  the 
study  was  to  compare  the  two  forms  of  adjuvant 
therapy evaluating RFS with secondary aims of eval-
uating OS and toxicity.  
The  aims  of  this  report  are  to  evaluate  the 
long-term RFS and identify subgroups of patients that 
may benefit from either form of adjuvant therapy and 
might modify the current practice modulation of 5FU 
by Leucovorin in selected patients. 
Patients and methods 
The reporting of this clinical trial is in accordance 
with the CONSORT- consensus statement23. 
Participants: A national prospective randomized 
clinical  trial  was  conducted  following  approval  by 
participating  medical  center  Institutional  Review 
Boards.  Between  1990  and  1995,  398  patients  with 
pathological  AJCC  Stage  II-III  colorectal  cancer  un-
derwent complete (R0) resection at four cancer centers 
in Israel. These patients were then randomly assigned 
to  receive  either  5FU+LV  (n=210)  or  5FU+LEV 
(n=188) for 12 months. To be eligible patients under-
went operation within 6 weeks of study entry, had 
Karnofsky Performance Status score > 85%, and were 
over the age of 18 years. Patients with recurrent dis-
ease, those who received prior chemotherapy or had 
prior  malignancies,  as  well  as  patients  with  severe 
co-morbidities, residual or systemic disease were ex-
cluded. Patients with primary rectal cancer received 
adjuvant  radiation  therapy  independent  of  their 
group allocation. Patients with rectal cancer who were 
treated with  neaoadjuvant chemoradiation  were ex-
cluded  from  the  study.  Twenty  two  patients  were 
ineligible for this study (Figure 1).  Journal of Cancer 2011, 2 
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Figure 1: Study flow chart. 
 
 
 
Interventions: Patients were assigned randomly 
to receive either adjuvant 5FU+LEV (5FU 450 mg/m2 
i.v. bolus daily from days 1 to 5, then from day 28, 
every other week at a dose of 900 mg/m2 i.v. bolus for 
12 months + LEV 150mg orally from days 1 to 3, then 
from day 28, 150 mg orally for three consecutive days 
every two weeks for 12 months), or adjuvant 5FU+LV 
(5FU 375 mg/m2 i.v. bolus daily from days 1 to 5 + LV 
200 mg/m2 i.v. as a 10 minute infusion before 5FU 
administration; then from day 28, 5FU 900 mg/m2 i.v. 
bolus + LV 100 mg/m2 i.v. over 10 minutes infusion 
before  5FU  administration,  every  two  weeks  for  12 
months). Toxicity was assessed at each chemotherapy 
session and scored according to WHO criteria.  
Objectives: The principal aim of this trial was to 
determine if adjuvant 5FU+LV offered a statistically 
significant improvement in RFS. Secondary endpoints 
were OS and toxicity over adjuvant 5FU+LEV in the 
setting of completely resected CRC.  
Outcome: Follow-up data was obtained from the 
four participating institutions. Patients alive without 
recent follow-up data were contacted and their dis-
ease status was updated. The clinical outcomes stud-
ied  were  loco-regional  recurrence  (LRR),  distant  re-
currence (DR), relapse-free survival (RFS), and overall 
survival (OS). Time to recurrence, and OS were cal-
culated from the date of surgery. In defining DR, any 
distant  recurrence  following  definitive  surgery  was 
considered.  
Sample size: To achieve the probability of a Type 
I error at alpha = 0.05, a sample size of 400 subjects per 
group would have 80% power to detect a 10% abso-
lute difference in 5-year RFS between the two treat-
ment arms.  
 Randomization:  Randomization  was  balanced 
between the two treatment arms stratified by gender Journal of Cancer 2011, 2 
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(male vs. female), tumor location (colon vs. rectum), 
grade (low vs. high) and stage. Randomization was 
carried out with a stratified permuted block scheme 
using a separate randomization table for each partic-
ipating study site. The allocation sequence was gen-
erated by the study biostatistician. 
Statistical  methods:  The  rate  of  recurrence  or 
death  was  estimated  using  the  Kaplan-Meier  prod-
uct-limit method and statistical differences in RFS or 
OS were calculated by the log rank test24.  
Clinical and pathological covariates investigated 
in this study included: treatment arm, completion of 
therapy,  age,  gender,  and  ethnicity,  disease  stage, 
histological differentiation, tumor location (colon or 
rectum), family history of cancer, abnormal preopera-
tive CEA, and body mass index (BMI). Clinicopatho-
logic  factors  were  correlated  with  study  endpoints. 
Associations between categorical factors were studied 
with Fisher’s exact test or Chi-squared test, as appro-
priate. Toxicity grades were compared with Wilcoxon, 
Mann-Witney  Test  for  comparison  of  means.  Uni-
variate influence of prognostic factors on study end-
points was analyzed using a stratified log rank test25. 
Multivariate  analysis  based  on  Cox’s  proportional 
hazards regression model was used to associate co-
variate  to  time-dependent  endpoints  adjusted  for 
major  prognostic  stratifying  variables26.  The  clinical 
and pathological data were processed using SPSS-10® 
(SPSS, Chicago IL). A p value < 0.05 was considered 
statistically significant. All P values are two sided.  
 
Results 
Patient characteristics 
Between 1990 and 1995, 398 patients were ran-
domly assigned to receive either 5FU+LEV (N=188) or 
5FU+LV  (N=210)  (Figure  1,  Study  Flow).  Baseline 
demographic  data  are  reported  in  Table  1  demon-
strating  no  significant  imbalance  between  the  two 
treatment  groups.  Median  age  was  63  years  (range 
24-76  years)  with  a  slight  male  to  female  predomi-
nance.  The  majority  of  patients  in  the  study  were 
treated for adenocarcinoma of the colon (81%; rectum 
19%).  Two  hundred  forty-one  (60.6%)  patients  suc-
cessfully  completed  12  months  of  either  treatment 
protocol. There was no major difference in number of 
patients  completing  adjuvant  therapy  between  the 
5FU+LEV  group  (110/188,  58.5%)  and  the  5FU+LV 
group (131/210, 62.4%, p=0.15).  
Treatment was not completed according to the 
study protocol in 157 patients (39.4%) mainly due to 
toxicity (13.4%), disease recurrence (9.5%) or protocol 
violation (16.3%).  
Table 1: Patient and tumor characteristics. 
   
 
All 
patients 
(n=398)
   
5FU-LEV 
(n=188) 
 
5FU-LV 
(n=210) 
 
p 
Value 
Median age  63.0  61.8  61.3  0.31 
 Minimum  24.0       
 Maximum  76.0       
Gender        0.66 
 Male  210  97 (52%)  113 (54%)   
 Female  188  91 (48%)  97 (46%)   
Ethnicity        0.39 
 Ashkenazi    252  112 (60%)  140 (67%)   
 Non-Ashkenazi  131  67 (36%)  64 (30%)   
 Non-Jewish  15  9 (4%)  6 (3%)   
Anatomic loca-
tion 
      0.63 
 Colon   322  154 (82%)  168 (80%)   
 Rectum  76  34 (18%)  42 (20%)   
AJCC Stage        1.00 
 Stage II  197  93 (50%)  104 (50%)   
 Stage III  201  95 (50%)  106 (50%)   
Histological 
grade (differen-
tiation) 
 
 
    0.22 
 Well  100  49 (26%)  51 (24%)   
 Moderately    210  105 (56%)  105 (50%)   
 Poor    44  16 (9%)  28 (13%)   
 Not-recorded    17 (9%)  27 (13%)   
Performance 
status 
       
 0 
   
351  
 
169 
(48.2%) 
182 (51.8%)   
 1  44  20 (45.5%)  24 (54.5%)    
 2 
 
3 
 
1 (33.3) 
 
2 (66.7%) 
 
 
 
 
Toxicity  
The  vast  majority  of  the  toxic  events  in  both 
groups occurred between the 4th and the 9th month of 
therapy.  Although  the  absolute  number  of  toxic 
events were similar in both treatment groups, events 
of  treatment  discontinuation  occurred  earlier  in  the 
5FU+LEV group (p=0.02). Adverse effects related to 
adjuvant  systemic  therapy  differed  significantly  be-
tween  the  two  treatment  arms  (Table  2).  Increased 
frequency of Grade III-IV neurotoxicity was observed 
in  the  5FU+LEV  group  (p=0.02)  while  Grade  III-IV 
gastrointestinal toxicity predominated in the 5FU+LV 
group (p=0.03). Hematological toxicity was mild and 
no episode of febrile neutropenia occurred. There was 
no death potentially attributable to chemotherapeutic 
treatment. Despite the fact that there was no differ-
ence in the relative portion of patients who failed to 
complete the 12-month treatment protocol, only 71.7% 
of  5FU+LEV-treated  patients  received  treatment  for Journal of Cancer 2011, 2 
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more  than  6  months,  compared  to  80.9%  of  the 
5FU+LV  group,  p=0.04.  Age,  gender,  and  ethnicity, 
disease stage, tumor location (colon or rectum), and 
body mass index (BMI) had no association with tox-
icity. 
 
 
Table 2: Grade 3-4 toxicity profile of the 2 study arms. 
  5FU-LEV 
(n=188) 
 
5FU-LV 
(n=210) 
p Value 
 
 
Hematological  
grade 3-4 
     
  Anemia  2.0%  2.0%  0.67 
  Neutropenia  8.0%  14%  0.09  
  Thrombocytopenia  3.0%  4.0%  0.32 
Neurological grade 3-4       
  Ataxia  9.6%  3.8%  0.02 
  Dizziness  28.7%  18.6%  0.05 
Gastrointestinal grade 3-4        
  Diarrhea  0.0%  2.0%  0.03 
  Nausea  0.0%  3.0%  0.02 
Muco-cutaneous grade 3-4       
  Stomatitis  0.0%  1.0%  0.74   
  Alopecia (partial) 
 
0.0% 
 
0.0% 
 
0.26 
 
 
 
 
Disease outcome: Relapse-free Survival  
Actuarial (Kaplan-Meier) survival analysis was 
performed in January 2004 with a median overall fol-
low up time of 99 months for the entire group, and 138 
months for the patients alive at time of last contact. 
Ten patients (2.5%) were lost to follow-up. Recurrence 
data was unavailable for 13 patients, leaving 385 pa-
tients for relapse-free analysis. There were 122 relapse 
events in the entire study group, 54 in the 5FU+LEV 
and 68 in the 5FU+LV group (p=0.59).  
Distribution of recurrence (35 local-regional and 
87 distant) by anatomic location for the entire study 
group  is  summarized  in  Table  3.  There  were  16 
(13.1%) delayed (>5years) recurrence events, 9 in the 
5FU+LEV and 7 in the 5FU+LV group. The latest re-
currence  occurred  113  months  after  randomization. 
Five-  and  ten-year  RFS  rates  for  the  5FU+LEV  and 
5FU+LV  groups  were  similar,  72%  and  61%  versus 
67%  and  60%  (p=0.88),  respectively,  and  were  not 
influenced by any clinical variable recorded.  
 
 
Table 3: Relapse by location. 
Locoregional:  35 
Distant:   
Hepatic  46 
Pulmonary  22 
Peritoneal  5 
Brain  1 
Unspecified distant recurrence  13 
Total 
 
122 
 
 
 
Disease outcome: Overall Survival  
Survival  status  at  the  time  of  analysis  was 
available  for  all  study  patients  (n=398);  156  died 
(5FU+LEV,  n=74  vs.  5FU+LV,  n=82).  Five-  and 
ten-year  OS  rates  for  the  5FU+LEV  and  5FU+LV 
groups were similar, 75% and 53% versus 72% and 
59%, respectively, and were not significantly different 
when  analysis  was  confined  only  to  those  patients 
completing treatment (p=0.64).  
Exploratory  sub-group  analysis  found  signifi-
cantly better OS patients who completed more than 6 
months of therapy versus those that did not, overall 
(p=0.002)  and  in  each  study  group  (5FU+LEV,  p= 
0.046; 5FU+LV, p=0.02: Figure 2 A, B, C). 
Gender-specific  subset  analysis  identified  a 
trend toward improved RFS and statistically signifi-
cant improved OS for female patients (10-year OS: M 
vs. F = 53% vs. 64%; p=0.04, Figure 3a). This difference 
was evident only in the 5FU+LEV group (5FU+LEV: 
10-year OS: M vs. F = 46% vs. 71%; p=0.04, Figure 3b).  
On a Cox stepwise regression multivariate anal-
ysis only AJCC Stage III emerged as an independent 
predictor  of  relapse-free  and  overall  survival  (RFS: 
RR=3.43  [95%  CI  2.08-5.66],  p=0.0001;  OS:  RR=1.5 
[1.3-1.8], p=0.001).  
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Figure 2: Overall survival as a function of protocol completion. Patients who completed 12 months of either treatment 
protocol had significantly better overall survival as compared to patients who discontinued their treatment before com-
pletion of at least 6 months of therapy. This survival difference was seen when all study patients (A) and for each of the study 
arms (B, C). Journal of Cancer 2011, 2 
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Figure 3: Survival as a function of gender. The overall survival of female patients was significantly better than that of male 
patients (A). Mean survival was 102.4 (95% C.I 95.1-109.7) and 113.7 (95% C.I 106.3-121.4) months for the male and the 
female groups respectively, log -rank p=0.04. In the 5FU+LEV group (n=188). The overall survival of female patients (n=91) 
was significantly better than the OS of male patients (n=97) in the 5FU+LEV group (B). Mean survival was 96.3.4 (95% C.I 
86.0-106.6) and 119.9 (95% C.I 109.9-129.8) months for the male and the female groups respectively, log -rank p=0.04. In the 
5FU+LV group (n=210). The overall survival of female patients (n=97) was no different than the OS of male patients (n=113) 
in the 5FU+LV group. Mean survival was 107.8 (95% C.I 98.3-117.4) and 107.2 (95% C.I 96.6-117.8) months for the male and 
the female groups respectively, log -rank p=0.10. Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
184 
 
Discussion 
 This ICOG trial was designed at a time when 
Levamisole-modulated  5-FU  was  standard  adjuvant 
chemotherapy for node-positive (Stage III) CRC. The 
principal aim of the study was to evaluate RFS with 
secondary aims of OS as well as toxicity evaluation in 
patients with Stage II/III CRC randomized to receive 
12  months  of  Leucovorin  (5FU+LV)-  or  Levamisole 
(5FU+LEV)-modulated  5FU  following  potentially 
curative resection. Both LV- and LEV- modulated 5FU 
in  this  study  were  well  tolerated  with  no  treat-
ment-related  mortality.  Ten-year  RFS  and  OS  were 
similar between treatment groups, as was Grade III 
toxicity;  however,  neurotoxicity  was  significantly 
more likely with 5FU+LEV, and gastrointestinal tox-
icity with 5FU+LV. Female patients had significantly 
improved OS over male patients (10-year, 64% v. 53%, 
p=0.04),  a  benefit  observed  only  in  the  5FU+LEV 
treated arm.  
The standard of care in adjuvant therapy for pa-
tients with resected AJCC Stage III colon cancer is 6 
months of 5FU+LV with an estimated 33% reduction 
in  the  risk  of  disease  recurrence27.  Current  practice 
guidelines  for  adjuvant  treatment  of  Stage  II  CRC 
remain  controversial28.  Adjuvant  5FU+LV  and 
5FU+LEV were compared in three clinical trials17,18,21. 
In the Intergroup 0089 trial, there was no significant 
difference in RFS or OS between the 5 treatment arms. 
The NSABP CO-4 trial demonstrated improved RFS 
and OS for patients treated with 6 months of adjuvant 
5FU+LV  compared  to  12  months  of  5FU+LEV.  The 
NCCTG 894651 trial showed that a three-drug regi-
men, 5-FU/LEV/LV for 6 months resulted in longer 
OS than 6 months of adjuvant 5-FU+LEV. However, 
5-FU+LEV for 12 months were shown to be as effec-
tive as the three-drug regimen.  
The results of our ICOG trial showed no difference 
in  either  5-year  or  10-year  RFS  or  OS  between 
5FU+LEV  and  5FU+LV;  however,  this  trial  did  not 
have  sufficient  statistical  power  to  detect  small  dif-
ferences in outcome between the treatment arms, and 
it was not designed with  sufficient power to deter-
mine treatment effect prospectively in specific patient 
subsets.  
Present-day  novel  agents  were  not  used  rou-
tinely  as  salvage  therapy  during  the  course  of  this 
study. In our study, the 5-year OS rates were 85% and 
63% for Stage II and III CRC, respectively, which are 
comparable  to  previously  published  reports20.  Also, 
there was a trend towards improved RFS and signifi-
cantly improved OS in female patients. Although in 
larger studies11,19 gender did not appear to influence 
outcome,  in  a  retrospective  analysis  of  5-FU+LEV 
12-month29 survival benefit was observed in female 
patients  with  right-sided  microsatellite  unstable  tu-
mors. The hypothesis-generating finding of improved 
long-term OS and a trend towards improved RFS in 
female patients treated with 5FU+LEV as compared to 
5FU+LV in the current ICOG trial was not reported 
previously in prospective adjuvant trials. If this pre-
liminary  observation  is  verified  in  meta-analysis  of 
randomized  clinical  trials,  then  female  patient 
sub-groups may indeed benefit from modulation of 
5FU by Levamisole in the context of modern systemic 
therapy regimens.  
The toxicity profile differed somewhat between 
5FU+LEV  and  5FU+LV  treatment  groups.  These 
findings are consistent with those of others21; howev-
er, it is important to note that patients in the 5FU+LEV 
group showed a tendency to earlier discontinuation of 
adjuvant  therapy  due  to  treatment-related  toxicity. 
Despite the introduction of novel therapeutic agents 
for CRC, LV-modulated 5FU remains an essential part 
of existing multi-agent adjuvant treatment protocols30.  
Since  the  completion  of  the  current  study,  the 
addition of Oxaliplatin to 5FU+LV evaluated in the 
MOSAIC trial31 was found to prolong event-free sur-
vival relative to 5FU+LV alone in Stage III CRC.  
Despite  advances  in  terms  of  progression-free 
survival for targeted therapy in advanced (Stage IV) 
CRC, LV-modulated 5FU with or without Oxaliplatin 
remains a modern-day standard adjuvant therapy in 
non-metastatic,  node-positive  CRC.  Considering  the 
findings  of  the  current  ICOG  Trial,  5FU+LEV  may 
remain a viable option in selected groups of CRC pa-
tients. The fact  that 13% of CRC recurrences devel-
oped after >5 years of follow-up, provides key insight 
into  the  natural  history  of  the  disease  and  further 
underscores the importance of long-term follow-up of 
patients with CRC. 
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